多发性骨髓瘤治疗的心脏并发症
Aatif Khurshid1, William H Frishman1, Wilbert S Aronow2
1From the Departments of Cardiology.
Cardiology in review
|September 10, 2024
概括
多发性骨髓瘤 (MM) 是血细胞的癌症. 本综述总结了MM治疗方法,重点关注其心脏毒性,以帮助在这个不断变化的领域的临床决策.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤 (MM) 起源于血细胞,导致骨髓中单克隆免疫球蛋白的产生.
- 恶性血细胞增殖会导致诸如骨病,高血症,贫血和功能障碍等并发症.
研究的目的:
- 对多发性骨髓瘤的当前和历史治疗选择进行审查和分类.
- 专门分析与各种多发性骨髓瘤治疗相关的心脏毒性.
主要方法:
- 对既有和新兴多发性骨髓瘤治疗的文献综述.
- 基于作用机制和临床利用的治疗方法的分类.
- 对每种治疗方式报告的心脏毒性影响进行了集中分析.
主要成果:
- 确立的MM治疗方法包括化疗,免疫疗法和干细胞移植.
- 新型疗法包括蛋白酶体抑制剂,免疫调节药物和单克隆抗体.
- 某些药物与显著的心脏毒性有关,需要仔细监测患者.
结论:
- 多发性骨髓瘤的治疗正在迅速发展,需要对治疗选择有全面的了解.
- 对心脏毒性的认识对于优化患者护理和管理与治疗相关的不良事件至关重要.
- 需要进一步的研究来开发更安全,更有效的MM疗法.
更多相关视频
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.6K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
相关概念视频
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents
543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
